RSV Injection

We expect to see our annual spike in RSV infections in the next few months.  As many of you are aware, respiratory syncytial virus (RSV) is a common respiratory infection that can be very serious, especially for our youngest patients.  Luckily two preventative measures have been introduced that will decrease the severity and frequency of infection caused by RSV.  These two treatment options include immunizing pregnant mothers with an RSV vaccine OR providing babies an injection of antibodies (Beyfortus or Enflonsia) designed to protect against the RSV virus.  The antibody injection is recommended for babies who are under 8 months at the beginning of RSV season (October).

We encourage our pregnant parents to discuss the Abrysvo vaccine with their obstetricians.  Pregnant women, who receive Abrysvo and deliver at least 14 days later, will provide significant antibodies against RSV to their babies. 

At Roswell Pediatric Center, we are offering the RSV antibody injection.  Last year, a single injection reduced RSV-associated hospitalizations by up to 90%!   It is given between October 1 and March 31 (RSV season) but preferably in October and November before RSV peaks in our community (usually December and January).  We encourage families to contact their insurance carriers BEFORE your next check-up in October or November to determine if your insurance covers the injection.  Your insurance can check your coverage with the following codes:

• Preferred: Enflonsia (CPT code 90382), plus injection (CPT96372) BUT if not covered then check on:
• for infants under 11 lbs: Beyfortus (CPT 90380)  plus injection (CPT 96372) 
• for infants over 11 lbs and under 8 months: Beyfortus (CPT 90381) plus injection (CPT 96372) 

We plan to offer the RSV injection at the following checkups starting October 1: newborn hospital followup and 2 week, 2 month, 4 month and 6 month checkups.  If your child already had their 6 month checkup and is under 8 months of age or their next checkup is not until December, we will have procedure visits available during October and November for administration.  

Additionally, there are a few high-risk patients who should receive Beyfortus between 8-18 months of age.  Ask your provider if you think your 8-18 month old child qualifies as high risk.